1662 completed, 570 recruiting, 490 unknown, 434 terminated. 1328 Phase 2, 1147 Phase 1, 534 Not applicable, 308 Phase 3, 55 Early Phase 1.
Follow Ovarian Neoplasms: new trials by email Literature Review of Ovarian Neoplasms trials Research Report on Ovarian Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors Exercise and dietary recommendations - Ovarian Cancer | Not applicable | Not yet recruiting | Oncare Madrid | 32 | 2028-05-01 | 2026-10-08 |
| PITCH - Impacting Hereditary Cancer Testing Genetic testing education video - Ovarian Cancer, Genetic Testing | Not applicable | Not yet recruiting | Rachel Miller | 200 | 2027-04-01 | 2026-09-10 |
| A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03) R-DXd, Bevacizumab - Fallopian Tube Cancer, Primary Peritoneal Cancer | Phase 3 | Not yet recruiting | Daiichi Sankyo | 600 | 2027-03-31 | 2026-11-13 |
| Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer losartan, Paclitaxel - Platinum Resistant Ovarian Cancer | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 27 | 2027-02-01 | 2026-09-22 |
| NK521 in the Treatment of Advanced Solid Tumors NK521 Cell Injection - Hepatocellular Carcinoma (HCC), Ovarian Cancer | Early Phase 1 | Not yet recruiting | Base Therapeutics (Shanghai) Co., Ltd. | 18 | 2027-01-01 | 2026-09-30 |
| PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian Cancer Upfront cytoreductive surgery, Interval debulking surgery, Platinum-based chemotherapy - Epithelial Ovarian Cancer, Fallopian Tube Cancers | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Gynecologic Oncology Group | 534 | 2026-12-31 | 2026-11-12 |
| Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab Fludarabine, Cyclophosphamide - Ovarian Cancer | Phase 2 | Not yet recruiting | Medical University of South Carolina | 20 | 2026-12-01 | 2026-07-22 |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1 INCB123667, Bevacizumab, Placebo - Ovarian Cancer | Phase 3 | Not yet recruiting | Incyte Corporation | 590 | 2026-12-01 | 2026-10-02 |
| Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial Imlunestrant, Abemaciclib, Selinexor - Low Grade Ovarian Serous Adenocarcinoma, Endometrial Cancer | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 60 | 2026-12-01 | 2026-09-21 |
| A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer QLS5132, Liposomal Doxorubicin, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 420 | 2026-12-01 | 2026-11-09 |
| A Study of LY4336619 in Adult Participants With Advanced Solid Tumors LY4336619, Sofetabart Mipitecan (Sofe-M) - Endometrial Neoplasms, Ovarian Neoplasms | Phase 1 | Not yet recruiting | Eli Lilly and Company | 370 | 2026-12-01 | 2026-11-10 |
| Identifying Mediators of Exercise-induced Tumor Microenvironment Remodeling to Enhance Primary Chemotherapy Response (IMPROVE-Ovarian) Exercise, Usual Care - High Grade Serous Ovarian, Ovarian Adenocarcinoma | Not applicable | Not yet recruiting | University of Pittsburgh | 20 | 2026-12-01 | 2026-11-12 |
| CYTALUX Dose Extension Study CYTALUX (pafolacianine) injection - Cancer in the Lung, Ovarian Cancer | Phase 4 | Not yet recruiting | On Target Laboratories, LLC | 106 | 2026-11-15 | 2026-11-09 |
| Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors QLS5133; Lenvatinib mesylate, QLS5133; QL2107; Lenvatinib mesylate, QLS5133; Bevacizumab - Clear Cell Renal Cell Carcinoma, Ovarian Cancer | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 558 | 2026-11-15 | 2026-11-12 |
| A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001) MK-6255, CD8 PET Tracer, Acetaminophen - Ovarian Neoplasms, Endometrial Neoplasms | Phase 1 | Not yet recruiting | Merck Sharp & Dohme LLC | 80 | 2026-11-13 | 2026-10-13 |
| MIRV in Combination With Suvemcitug for Partially Platinum-Sensitive Ovarian Cancer Mirvetuximab Soravtansine, Suvemcitug - Platinum-Sensitive Recurrent Ovarian Cancer | Phase 2 | Not yet recruiting | Tongji Hospital | 80 | 2026-11-10 | 2026-11-12 |
| Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer CryptiVax-1001 - Ovarian Cancer, HGSOC | Phase 1 | Recruiting | Epitopea Ltd | 50 | 2026-11-05 | 2026-11-10 |
| Safety in Ovarian Cancer for Average-Risk Women - Analysis Blood-Based Ovarian Cancer Screening Test - Ovarian Cancer | Not applicable | Not yet recruiting | Mercy BioAnalytics, Inc. | 1750 | 2026-11-01 | 2026-10-16 |
| Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer Rina-S, Bevacizumab - Ovarian Cancer | Phase 3 | Not yet recruiting | Genmab | 602 | 2026-11-01 | 2026-10-05 |
Showing 20 of 3701. Sign in to see all of them.
Carcinoma, Ovarian Epithelial (787) · Fallopian Tube Neoplasms (784) · Breast Neoplasms (683) · Endometrial Neoplasms (452) · Neoplasms (365) · Uterine Cervical Neoplasms (361) · Carcinoma, Non-Small-Cell Lung (339) · Pancreatic Neoplasms (325) · Colorectal Neoplasms (320) · Stomach Neoplasms (268) · Prostatic Neoplasms (256) · Lung Neoplasms (254) · Melanoma (212) · Sarcoma (183)
Urogenital Diseases (3701) · Female Urogenital Diseases (3700) · Female Urogenital Diseases and Pregnancy Complications (3700) · Genital Diseases (3700) · Gonadal Disorders (3695) · Endocrine System Diseases (3694) · Adnexal Diseases (3693) · Genital Diseases, Female (3686) · Neoplasms by Site (3682) · Urogenital Neoplasms (3678) · Endocrine Gland Neoplasms (3672) · Ovarian Diseases (3671) · Genital Neoplasms, Female (3663) · Neoplasms (3336) · Neoplasms by Histologic Type (1435)
Paclitaxel (380) · Carboplatin (372) · Bevacizumab (209) · liposomal doxorubicin (123) · Gemcitabine (121) · pembrolizumab (119) · Cisplatin (108) · Cyclophosphamide (104) · Topotecan (104) · olaparib (101) · niraparib (74) · Taxes (71) · Docetaxel (60) · Doxorubicin (52) · Drug Therapy (50)
National Cancer Institute (NCI) (190) · Memorial Sloan Kettering Cancer Center (84) · M.D. Anderson Cancer Center (80) · Gynecologic Oncology Group (77) · AstraZeneca (63) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (42) · Dana-Farber Cancer Institute (37) · Eli Lilly and Company (32) · Mayo Clinic (28) · City of Hope Medical Center (26) · Masonic Cancer Center, University of Minnesota (26) · University Health Network, Toronto (26) · Pfizer (25) · ARCAGY/ GINECO GROUP (24) · Fred Hutchinson Cancer Center (24)
United States (1995) · China (406) · France (315) · Canada (301) · United Kingdom (300) · Spain (283) · Italy (282) · Belgium (206) · Germany (203) · Australia (189) · South Korea (183) · Netherlands (135) · Japan (121) · Denmark (103) · Israel (99)
Lei Li, M.D. (14) · Paul Sabbatini, MD (13) · Amit Oza (7)
PMID 37185961, PMID 37407274, PMID 35170751, PMID 39695768, PMID 19238149, PMID 30633128, PMID 20818904, PMID 23922302, PMID 26961146, PMID 29342393, PMID 35537408, PMID 36512649, PMID 39019698, PMID 16394300, PMID 21941283, PMID 26707054, PMID 34904813, PMID 35262624, PMID 35397664, PMID 40132910, PMID 41044356, PMID 12826431, PMID 16882940, PMID 16966687, PMID 17000396, PMID 17949799, PMID 19282241, PMID 19427025, PMID 19556464, PMID 19949018, PMID 22002018, PMID 24378877, PMID 24637997, PMID 25209242, PMID 26588236, PMID 27998224, PMID 28665051, PMID 28935273, PMID 29343557, PMID 29995186, PMID 31046081, PMID 31685558, PMID 32073956, PMID 32379297, PMID 33337539, PMID 33538338, PMID 33960681, PMID 35254001, PMID 35289396, PMID 36055959
U10CA027469 (59), U10CA180868 (45), 2023 (33), 2018 (23), 2025 (22), P30CA033572 (18), 2017 (17), 2008 (16), 2015 (15), 2016 (15), P30CA015083 (14), 2009 (13), U10CA101165 (11), 2019 (9), P30CA016672 (9)